ClinicalTrials.gg
CompletedNCT06609512Updated Feb 7, 2025

A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)

A Phase 1 interventional study of Enlicitide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of the study is to learn what happens to enlicitide decanoate in a healthy person's body over time when taken on an empty stomach or with food. Researchers will compare what happens to enlicitide in a healthy person's body over time when enlicitide is taken with or without food. Enlicitide decanoate will be referred to as "enlicitide" throughout.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has (BMI) ≥18 kg/m\^2 and ≤32 kg/m\^2

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History of gastrointestinal disease which may affect food and drug absorption, or has had a gastric bypass or similar surgery
  • History of cancer ()
  • Positive test(s) for surface antigen (HBsAg), antibodies or (HIV)
  • History of a major surgery
  • Is lactose intolerant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Enlicitide Treatment A

    Participants receive single oral dose of enlicitide after 8-hour overnight fast.

    Drug: Enlicitide

  • Experimental
    Enlicitide Treatment B

    Participants receive single oral dose of enlicitide 4 hours after morning meal.

    Drug: Enlicitide

  • Experimental
    Enlicitide Treatment C

    Participants receive single oral dose of enlicitide 3 hours after morning meal.

    Drug: Enlicitide

  • Experimental
    Enlicitide Treatment D

    Participants receive single oral dose of enlicitide 2 hours after morning meal.

    Drug: Enlicitide

Interventions

  • Oral Tablet

    Also known as: MK-0616, enlicitide decanoate

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration versus Time Curve from 0 to Infinity (AUC0-inf) of enlicitide in plasma

    AUC0-inf of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

  2. Area Under the Concentration versus Time Curve from Time 0 to 24 hours (AUC0-24) of enlicitide in plasma

    AUC0-24 of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 24 hours post dose

  3. Area under the concentration versus time curve from time 0 to last quantifiable sample (AUC0-last) of enlicitide in plasma

    AUC0-last of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

  4. Maximum plasma concentration (Cmax) of enlicitide in plasma

    Cmax of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

  5. Time to maximum plasma concentration (Tmax) of enlicitide in plasma

    Tmax of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

  6. Apparent terminal half-life (t1/2) of enlicitide in plasma

    t1/2 of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

  7. Apparent Clearance (CL/F) of enlicitide in plasma

    CL/F of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

  8. Apparent volume of distribution during terminal phase (Vz/F) of enlicitide in plasma

    Vz/F of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

  9. Lag Time (tlag) of enlicitide in plasma

    tlag is the time from dosing to the first appearance in plasma. The tlag of enlicitide in plasma will be determined.

    Time frame: Pre-dose and at designated time points up to 168 hours post dose

Secondary outcomes

  1. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~ 14 days

  2. Number of participants who discontinue study intervention due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~ 14 days

07

Study locations

1 site
  • Celerion ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jan 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 24, 2024
StartActual
Oct 21, 2024
Primary completionActual
Jan 13, 2025
CompletionActual
Jan 31, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06609512
Responsible party
Sponsor
First posted
Sep 24, 2024
Start date
Oct 21, 2024
Primary completion
Jan 13, 2025
Completion
Jan 31, 2025
Last update
Feb 7, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide

Start the discussion